Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 1:30 p.m. ET. The event aims to showcase Vaxcyte's innovative vaccine development efforts, including its lead candidate, VAX-24, a preclinical pneumococcal conjugate vaccine designed for preventing invasive pneumococcal disease. A live webcast will be available through the company's website, with a replay offered for 30 days post-conference. Vaxcyte is focused on creating novel vaccines to address common infectious diseases globally.

FOSTER CITY, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 20^th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET.

A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF^™ platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.

Contact:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

FAQ

When is Vaxcyte participating in the Needham Virtual Healthcare Conference?

Vaxcyte will participate in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 1:30 p.m. ET.

What is Vaxcyte's lead vaccine candidate?

Vaxcyte's lead vaccine candidate is VAX-24, a preclinical pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease.

How can I watch Vaxcyte's fireside chat?

The fireside chat can be accessed via the Investors & Media section of Vaxcyte's website, with a replay available for about 30 days after the conference.

What is the purpose of Vaxcyte's vaccine development?

Vaxcyte aims to improve global health by developing superior and novel vaccines to prevent or treat common and deadly infectious diseases.

What are some other candidates in Vaxcyte's pipeline?

Vaxcyte's pipeline includes VAX-XP, a pneumococcal conjugate vaccine covering at least 30 strains; VAX-A1, a vaccine for Group A Strep; and VAX-PG, targeting periodontal disease.